UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2023

		UPEXI, INC.	
		(Exact name of registrant as specified in its charter)	
	Nevada	333-25526	83-3378978
	(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
		17129 US Hwy 19 N. Clearwater, FL 33760 Address of Principal Executive Offices) (Zip Code)	
	((701) 353-5425 Registrant's telephone number, including area code)	
	(Form	Not Applicable mer name or former address, if changed since last rep	port)
Check th	ne appropriate box below if the Form 8-K filing is inter	nded to simultaneously satisfy the filing obligation of	f the registrant under any of the following provisions:
□ S □ P	Vritten communications pursuant to Rule 425 under the oliciting material pursuant to Rule 14a-12 under the Extre-commencement communications pursuant to Rule 1 re-commencement communications pursuant to Rule 1	xchange Act (17 CFR 240.14a-12) .4d-2(b) under the Exchange Act (17 CFR 240.14d-2	
Securitie	es registered pursuant to Section 12(b) of the Act:		
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
	Common Stock, par value \$0.001	UPXI	NASDAQ
	by check mark whether the registrant is an emerging grities Exchange Act of 1934 (§240.12b-2 of this chapter		rities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
Emergin	g growth company ⊠		
	erging growth company, indicate by check mark if the ng standards provided pursuant to Section 13(a) of the		ition period for complying with any new or revised financial

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition.

On May 15, 2023, Upexi, Inc. (the "Company") issued a press release announcing financial and operational results and business highlights for the three and nine months ended March 31, 2023 (the "Press Release"). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Form 8-K (including Exhibit 99.1) is being "furnished," and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Exhibit Description
99.1	Press Release of Upexi, Inc., dated May 15, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GROVE, INC.

Dated: May 18, 2023

/s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer



Upexi Reports Revenue of \$24.2 Million for Fiscal 2023 Third Quarter, an Increase of 447% Year-Over-Year

Clearwater, FL, May 15, 2023 (GLOBE NEWSWIRE) – Upexi, Inc. (NASDAQ: UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal 2023 third quarter ending March 31, 2023.

Fiscal 2023 Third Quarter Financial Highlights:

- · Revenue totaled \$24.2 million, an increase of 447%, as compared to \$4.4 million for the same period the prior year.
- Gross profit totaled \$9.6 million, an increase of 189%, as compared to \$3.3 million for the same period the prior year.
- · Adjusted EBITDA for the quarter totaled a positive \$671,339 as compared to an adjusted EBITDA loss of \$877,351 for the same period in the prior year.
- Net loss attributable to Upexi, Inc. shareholders was \$1.6 million as compared to a net loss of approximately \$0.05 million for the same period in the prior year.
- Shareholder equity increased by \$7.7 million to \$36.1 million as compared to \$28.4 million for the same period in the prior year.
- · Cash and cash equivalents totaled \$1.2 million as of March 31, 2023. Subsequent to quarter, Upexi announced a common-only financing of \$7 million.

"We are pleased with the organic growth of our key brands during the quarter, driving 447% quarterly year-over-year growth to \$24.2 million. We increased positive Adjusted EBITDA to \$671,000 for the quarter on a lower revenue base from last quarter. This is encouraging progress in a short amount of time and due to our determined optimization strategy," stated Allan Marshall, Upexi's Chief Executive Officer. "Management expects this trend to continue throughout the remainder of calendar 2023. We anticipate that revenue will continue to grow and that we will meet or exceed our \$100 million projection, as will Adjusted EBITDA. These projections do not include recent developments such as Disney or the Non-Binding LOI issued April 13, 2023. The Company will update guidance in the future as needed as the year progresses."

Fiscal 2023 Third Quarter and Subsequent Operational Highlights:

- Tytan Tiles announced a licensing agreement with The Walt Disney Company, including such key brands as Frozen, The Lion King, Toy Story, and Cars.
- Tytan Tiles announced expansion from 2,200 to over 3,900 Walmart locations.
- Announced agreement to acquire remaining 45% interest in Cygnet Online, one year ahead of guidance.
- Consolidated third party logistics locations to improve operating efficiencies and reduce distribution costs by \$1 to \$1.5 million.
- Signed Letter of Intent to acquire Wellness and Nutrition Brand with trailing twelve-month revenue of \$15 million.
- · Announced \$7 Million common-only financing.

Financial Highlights for Fiscal 2023 Third Quarter

Revenue for the three months ended March 31, 2023, totaled \$24.2 million, an increase of 447% as compared to \$4.4 million for the same period the year prior. The revenue growth was primarily the result of the three acquisitions and was offset from the sale of Infusionz. Management believes that there is significant opportunity in the next 12 months for organic growth within the newly acquired business and will focus the acquisition targets on businesses that will enhance our current products or allow the business to accelerate growth.

Cost of revenue during the quarter totaled \$14.6 million, compared to \$1.1 million for the same period the prior year. The cost of revenue growth was primarily related to the acquisition of four companies and offset with the sale of Infusionz.

Gross profit for the quarter was \$9.6 million, an increase of 190% as compared to \$3.3 million for the same period in the prior year. Management will seek to improve the gross profit and the overall gross margin in the next 12 months as they are able to leverage the significant increase in our purchasing requirements and continue to consolidate operations.

General and administrative expenses were \$2.9 million, an increase of \$900,000 or 46% compared with the same period last year. As the Company has changed with the acquisitions and the sale of Infusionz, management has managed the general and administrative costs and will continue to implement strategies to decrease the percentage of general and administrative costs when compared to total sales.

The Company had a net loss from continued operations of \$1.6 million for the three months ended March 31, 2023, compared to a net loss of \$52,667 for the same period in the prior year.

As of March 31, 2023, the Company had cash of \$1.2 million, a line of credit with \$4.9 million available, and stockholders' equity attributed to Upexi stockholders of \$36.1 million. On May 12, 2023, the Company announced a Registered Direct Offering of Common Stock for gross proceeds of approximately \$7 million before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or about May 16, 2023, subject to the satisfaction of customary closing conditions.

As of today, May 15, 2023 there are 18,094,748 shares of common stock outstanding.

Financial Results Conference Call

Event: Fiscal 2023 Third Quarter Financial Results Conference Call

Date: Monday, May 15, 2023

Time: 4:30 p.m. Eastern Time

Live Call: 1-877-300-8521 (U.S. Toll-Free) or 1-412-317-6026 (International)

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1613123&tp-key=7d65f8a311

For those unable to join the conference call, a dial-in replay of the call will be available until May 29, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 10178708.

Additional details are available under the Investor Relations section of the Company's website: https://upexi.com/investors.

About Upexi, Inc.:

Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year over year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house, SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.

FORWARD LOOKING STATEMENTS:

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1934 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Adjusted EBITDA

Aujusta Ebiiba	Three Months Ended 31-Mar-23 31-Mar-22 \$ (1,643,883) \$ (52,667) \$ 154,999 \$ 19,705 \$ 1,923,735 \$ 351,012 \$ (496,880) \$ (1,351,686) \$ 1,146,299 \$ 854,013 \$ - \$ (5,500) \$ - \$ -		
	 1-Mar-23	31-Mar-22	
Net income (Net loss) GAAP	\$ (1,643,883)	\$ (52,6	67)
Interest expense, net	\$ 154,999	\$ 19,7	05
Depreciation and amortization	\$ 1,923,735	\$ 351,0)12
Income Tax	\$ (496,880)	\$ (1,351,6	(86
Stock Compensation	\$ 1,146,299	\$ 854,0)13
Gain on sale of asset	\$ -	\$ (5,5	00)
Change in derivative liability	\$ -	\$	-
Loss from discontinued operations	\$ (288,127)	\$ (147,5	83)
Loss attributable to non-controlling interest	\$ (124,804)	\$	-
	\$ 671,339	\$ (332,7	(06)

Company Contact Andrew Norstrud, Chief Financial Officer Email: andrew.norstrud@upexi.com Phone: (702) 332-5591

Investor Relations Contact

KCSA Strategic Communications Valter Pinto or Jack Perkins Email: Upexi@KCSA.com Phone: (212) 896-1254

		Three Months Ended March 31,			Nine Months Ended March 31,			
	_	2023		2022		2023		2022
Revenue								
Revenue	\$	24,219,445	\$	4,426,898	\$	62,863,128	\$	13,280,565
Cost of Revenue		14,614,754		1,098,137		36,904,527		3,081,112
Gross profit	_	9,604,691		3,328,761	_	25,958,601		10,199,453
Operating expenses								
Sales and marketing		3,476,918		1,085,823		9,210,303		3,821,081
Distribution costs		2,578,180		605,368		8,641,559		1,538,830
General and administrative expenses		2,878,255		1,970,276		8,287,779		6,556,627
Share-based compensation		1,146,299		854,013		3,126,472		2,333,306
Amortization of acquired intangible assets		1,691,243		236,001		3,534,216		
1 0								540,836
Depreciation	<u> </u>	232,492 12,003,387	_	4,866,492	_	33,469,869		361,590 15,152,270
		12,005,507						
Loss from operations		(2,398,696)		(1,537,731)		(7,511,268)		(4,952,817
Other income (expense), net								
Interest (expense) income, net		(154,999)		(19,705)		(2,380,972)		(61,699
Change in derivative liability		_		_		(1,770)		
Gain on sale of Infusionz and select assets		_		_		7,564,363		
Gain (loss) on sale of property and equipment		_		5,500		7,501,505		5,500
Gain on SBA PPP loan extinguishment	_	-				<u>-</u>		300,995
Other income (expense), net		(154,999)		(14,205)		5,181,621		244,796
Net loss before income tax		(2,553,695)		(1,551,936)		(2,329,647)		(4,708,021
Income tax benefit		496,880		1,351,686		449,828		1,116,653
Net loss from continuing operations		(2,056,815)		(200,250)		(1,879,819)		(3,591,368
• •								
Loss (income) from discontinued operations		288,127		147,583		(50,291)		4,115,245
Net loss attributable to non-controlling interest	_	124,804	_	<u>-</u>	_	358,390	_	
Net (loss) income attributable to Upexi, Inc.	<u>\$</u>	(1,643,884)	\$	(52,667)	\$	(1,571,720)	\$	523,877
Basic income (loss) per share:								
Loss per share from continuing operations	\$	(0.11)	\$	(0.01)	\$	(0.11)	\$	(0.22
Income (loss) per share from discontinued operations	\$	0.02	\$	0.01	\$	(0.00)	\$	0.26
	_		_		_		_	
Total (loss) income per share	\$	(0.11)	\$	(0.00)	\$	(0.11)	\$	0.03
Diluted (loss) income per share:								
Loss per share from continuing operations	\$	(0.11)	\$	(0.01)	\$	(0.11)	\$	(0.20
Income (loss) per share from discontinued operations	\$	0.02	\$	0.01	\$	(0.00)	\$	0.23
Total (loss) income per share	\$	(0.11)	\$	(0.00)	\$	(0.11)	\$	0.03
Designation of the design of the Control of the Con		10.015.025		16.426.200		17 410 077		16,000,600
Basic weighted average shares outstanding Fully diluted weighted average shares outstanding	_	18,015,837		16,426,399	_	17,418,877		16,080,699
		18,015,837		17,821,810		17,418,877		17,586,030

CONDENSED CONSOLDIATED BALANCE SHEETS (UNAUDITED)

		March 31, 2023		June 30, 2022
SSETS				
Current assets				
Cash	\$	1,181,042	\$	7,149,806
Accounts receivable		5,346,853		1,137,637
Inventory		10,140,644		4,725,685
Due from Bloomios		1,617,216		
Deferred tax asset, current		-		462,070
Prepaid expenses and other receivables		1,809,730		840,193
Assets of discontinued operations, net		-		6,449,210
Total current assets		20,095,485		20,764,601
Property and equipment, net		7,618,148		7,343,783
Intangible assets, net		17,312,833		10,641,382
Goodwill		15,056,856		5,887,393
Deferred tax asset		2,979,918		2,002,759
Investments - Bloomios		9,955,450		2,002,700
Other assets		118,040		100,372
Right-of-use asset		678,145		926,570
Total other assets	_	53,719,390	_	26,902,259
Total outer assets	_	33,719,390	_	20,902,239
Total assets	\$	73,814,875	\$	47,666,860
IABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities				
Accounts payable	\$	2,635,876	\$	2,018,541
Accrued compensation	Ψ	889,634	Ψ	531,259
Deferred revenue		48,162		105,848
Accrued liabilities		4,172,455		955,327
Acquisition payable		500,000		933,32
Current portion of notes payable		9,164,189		5,424,752
Current portion of operating lease payable		272,116		267,029
Total current liabilities		17,682,429	-	9,302,756
Operating lease payable, net of current portion		449,874		700,411
Notes payable, net of current portion		18,951,762		8,876,949
Total long-term liabilities	_	19,401,636	_	9,577,360
		, ,		
commitments and contingencies				
tockholders' equity Preferred stock, \$0.001 par value, 100,000,000 shares authorized, 500,000 and 500,000 shares issued and				
outstanding, respectively		500		500
Common stock, \$0.001 par value, 100,000,000 shares authorized, 18,094,748 and 16,713,345 shares issued and		300		300
common stock, \$0.001 par value, 100,000,000 snares authorized, 18,094,748 and 16,713,345 snares issued and outstanding, respectively				
		18,094		16,713
Additional paid in capital		44,858,392		34,985,597
Accumulated deficit	_	(7,842,606)		(6,270,886
Total stockholders' equity attributable to Upexi, Inc.		37,034,380		28,731,924
Non-controlling interest in subsidiary		(303,570)		54,820
Total stockholders' equity		36,730,810		28,786,744
		73,814,875	\$	47,666,860